On September 27, 2024, Cooper Ronald Harold Wilfred, CEO of enGene Holdings Inc (ENGN, Financial), purchased 10,000 shares of the company, according to a recent SEC Filing. This transaction increased the insider's total holdings to 10,000 shares.
enGene Holdings Inc (ENGN, Financial) is a biotechnology firm focused on developing gene therapies for various medical conditions. The company's innovative approach aims to provide significant advancements in the treatment of diseases through genetic modifications.
The shares were bought at a price of $5.7 each, valuing the transaction at $57,000. Following this purchase, the market cap of enGene Holdings Inc stands at $307.298 million.
Over the past year, the insider transaction history at enGene Holdings Inc shows a balanced activity with 1 insider buy and 1 insider sell. The recent purchase by the CEO suggests a continuing confidence in the company's prospects.
For investors, understanding insider transactions can provide insights into a company's health and management's view of the company's future. Insider buys, in particular, may signal a management's positive outlook on the company's valuation and future performance.
For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can visit the respective links.
This insider buying activity might be a key indicator for stakeholders monitoring the company's stock and evaluating its potential for future growth.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
